Phathom Pharmaceuticals downgraded by Evercore ISI
$PHAT
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI downgraded Phathom Pharmaceuticals from Outperform to In-line
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $23.00 | Overweight | Cantor Fitzgerald |
| 5/3/2024 | $24.00 | Buy | Stifel |
| 1/5/2024 | $23.00 → $26.00 | Buy | Needham |
| 8/9/2023 | $28.00 | Buy | H.C. Wainwright |
| 5/11/2023 | In-line → Outperform | Evercore ISI | |
| 3/13/2023 | $21.00 | Buy | Craig Hallum |
| 10/21/2022 | $16.00 | Buy | Jefferies |
| 5/6/2022 | Outperform → In-line | Evercore ISI |
Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, August 7, 2025, to report its second quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A rec
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00
Stifel initiated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Needham reiterated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $26.00 from $23.00 previously
Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
3 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
SCHEDULE 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, August 7, 2025, to report its second quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A rec
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common
SC 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)